Telisotuzumab vedotin

Generic Name: Telisotuzumab vedotin

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1714088-51-3

Unique Ingredient Identifier: 976X9VXC3Z

Background: Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in ...

AbbVie to present new data on ADCs at ESMO 2024, including results from Phase 2 PICCOLO trial on mirvetuximab soravtansine for platinum-sensitive ovarian cancer and Phase 2 LUMINOSITY trial on telisotuzumab vedotin for advanced NSCLC. Also, new safety and efficacy data from Phase 1 study of ABBV-400 in pre-treated NSCLC and GEA patients.

Related Clinical Trials:

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

certara.com

8 months ago

Reflections on the New FDA Clinical Pharmacology Guidance for Antibody-Drug Conjugates

The FDA finalized guidance on Antibody-Drug Conjugates (ADCs) in March 2024, emphasizing clinical pharmacology strategies for development. Key areas include bioanalytical methods, dosing strategies, exposure-response analysis, intrinsic factors, QTc assessments, immunogenicity, pharmacogenomics, and drug-drug interactions. The guidance aids in optimizing ADC therapeutic indices and supports dose adjustments based on patient factors.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy